Please consult with our team for individualized recommendations.
Discover Our Peptide Portfolio In 2023, the FDA reviewed several peptides nominated for compounding and placed many on the 503A Category 2 list.[3] Then in 2024, the agency cited limited clinical safety data, along with concerns about immunogenicity (how the immune system might respond) and dosing variability.[4] It was a precautionary decision, and precaution is an important part of regulatory oversight
Five studies of BPC-157 reviewed by the agency were of short duration, had small sample sizes and evaluated doses that were likely exploratory in nature, the staffers said
BPC-157 for Gut Healing: Stomach Ulcers, IBS, Gastritis & GERD This blog explains how BPC-157, a peptide derived from gastric juice, may promote gut healing and recovery from digestive disorders such as stomach ulcers, gastritis, IBS, leaky gut, inflammatory bowel disease, and GERD
Being honest about what an adjunct can and cannot do is part of how we work